Evidence map›Paper›PMID 23752193›Full record

ArticleOncogene2014

A novel Ku70 function in colorectal homeostasis separate from nonhomologous end joining.

N Puebla-Osorio, J Kim, S Ojeda, H Zhang, O Tavana, S Li, Y Wang, Q Ma, K S Schluns, C Zhu

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. DNA and cell biology · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

N Puebla-OsorioDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J KimDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S OjedaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H ZhangDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
O Tavana1] Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.
S LiDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y WangDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Q Ma1] The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA [2] Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
K S Schluns1] Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.
C Zhu1] Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Ku70, a known nonhomologous end-joining (NHEJ) factor, also functions in tumor suppression, although this molecular mechanism remains uncharacterized. Previously, we showed that mice deficient for DNA ligase IV (Lig4), another key NHEJ factor, succumbed to aggressive lymphoma in the absence of tumor suppressor p53. However, the tumor phenotype is abrogated by the introduction of a hypomorphic mutant p53(R172P), which impaired p53-mediated apoptosis but not cell-cycle arrest. However, Lig4(-/-)p53(R172P) mice succumbed to severe diabetes. To further elucidate the role of NHEJ and p53-mediated apoptosis in vivo, we bred Ku70(-/-) p53(R172P) mice. Unexpectedly, these mice were free of diabetes, although 80% of the mutant mice had abnormally enlarged colons with pronounced inflammation. Remarkably, most of these mutant mice progressed to dysplasia, adenoma and adenocarcinoma; this is in contrast to the Lig4(-/-)p53(R172P) phenotype, strongly suggesting an NHEJ-independent function of Ku70. Significantly, our analyses of Ku70(-/-)p53(R172P) colonic epithelial cells show nuclear stabilization of β-catenin accompanied by higher expression of cyclin D1 and c-Myc in affected colon sections than in control samples. This is not due to the p53 mutation, as Ku70(-/-) mice share this phenotype. Our results not only unravel a novel function of Ku70 essential for colon homeostasis, but also establish an excellent in vivo model in which to study how chronic inflammation and abnormal cellular proliferation underlie tumorigenesis and tumor progression in the colon.

Indexed as

DNA End-Joining RepairHomeostasisAdenocarcinomaAnimalsAntigens, NuclearCarcinogenesisCell ProliferationCells, CulturedCellular SenescenceColonColorectal NeoplasmsCyclin D1Cyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsDNA DamageEpithelial CellsAntigens, NuclearCcnd1 protein, mouseCyclin D1Cyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsInterleukin-6interleukin-6, mouseKu AutoantigenMyc protein, mouseProto-Oncogene Proteins c-mycTumor Necrosis Factor-alphaTumor Suppressor Protein p53Xrcc6 protein, humanXrcc6 protein, mouse

Identifiers

PMID23752193
PMCPMC5761319
OpenAlexW2034243056

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.